Meeting
2019 ASCO Annual Meeting
Electrostatic human leukocyte antigen-neoantigen interactions and durable benefit in non-small cell lung cancer patients treated with immunotherapy.
Authors
Amy Lauren Cummings
David Geffen School of Medicine at UCLA, Los Angeles, CA
Amy Lauren Cummings , Jaklin Gukasyan , Henry Lu , Benji Bachrach , John Madrigal , James M. Carroll , Wisdom O Akingbemi , Zorawar Singh Noor , Aaron Elliott Lisberg , Edward B. Garon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2635)
DOI
10.1200/JCO.2019.37.15_suppl.2635
Abstract #
2635
Poster Bd #
279
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC).
First Author: Henry Lu
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2024 ASCO Annual Meeting
Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.
First Author: John M. Wrangle
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin-like receptor B2 (LILRB2).
First Author: Sandra Jones